Alane Izu to Antibodies, Bacterial
This is a "connection" page, showing publications Alane Izu has written about Antibodies, Bacterial.
Connection Strength
2,077
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
Score: 0,883
-
Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease. Vaccine. 2021 11 16; 39(47):6813-6816.
Score: 0,176
-
Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. Vaccine. 2015 Nov 27; 33(48):6793-9.
Score: 0,116
-
Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines. 2015; 14(12):1651-60.
Score: 0,115
-
HIV-1 Is Associated With Lower Group B Streptococcus Capsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women. J Infect Dis. 2015 Aug 01; 212(3):453-62.
Score: 0,111
-
Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines. 2015 Jan; 14(1):135-49.
Score: 0,108
-
Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. AIDS. 2014 Feb 20; 28(4):531-41.
Score: 0,103
-
Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One. 2013; 8(8):e72794.
Score: 0,100
-
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21; 31(5):777-83.
Score: 0,095
-
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med. 2023 Jul 20; 389(3):215-227.
Score: 0,050
-
Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial. Lancet Child Adolesc Health. 2023 05; 7(5):326-335.
Score: 0,048
-
Association of Group B Streptococcus (GBS) Serum Serotype-Specific Anticapsular Immunoglobulin G Concentration and Risk Reduction for Invasive GBS Disease in South African Infants: An Observational Birth-Cohort, Matched Case-Control Study. Clin Infect Dis. 2021 09 07; 73(5):e1170-e1180.
Score: 0,044
-
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
Score: 0,041
-
The Association Between Breast Milk Group B Streptococcal Capsular Antibody Levels and Late-onset Disease in Young Infants. Clin Infect Dis. 2020 03 03; 70(6):1110-1114.
Score: 0,039
-
Effect of HIV-exposure and timing of antiretroviral treatment initiation in children living with HIV on antibody persistence and memory responses to Haemophilus influenzae type b and pneumococcal polysaccharide-protein conjugate vaccines. Vaccine. 2020 03 10; 38(12):2651-2659.
Score: 0,039
-
An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates. Vaccine. 1999 Aug 06; 17(23-24):2999-3006.
Score: 0,009